Catalyst Pharmaceuticals Inc (CPRX)vsBeiGene, Ltd. (ONC)
CPRX
Catalyst Pharmaceuticals Inc
$31.49
0.00%
HEALTHCARE · Cap: $3.85B
ONC
BeiGene, Ltd.
$368.08
+0.66%
HEALTHCARE · Cap: $39.69B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 927% more annual revenue ($6.13B vs $596.96M). CPRX leads profitability with a 37.1% profit margin vs 10.7%. CPRX trades at a lower P/E of 18.2x. ONC earns a higher WallStSmart Score of 64/100 (C+).
CPRX
Buy62
out of 100
Grade: C+
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CPRX.
Margin of Safety
+80.0%
Fair Value
$1758.06
Current Price
$368.08
$1389.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 49.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Weak financial health signals
Trading at 8.0x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CPRX
The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 37.1% and operating margin at 49.0%.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bear Case : CPRX
The primary concerns for CPRX are Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 62.9x leaves little room for execution misses.
Key Dynamics to Monitor
CPRX profiles as a mature stock while ONC is a growth play — different risk/reward profiles.
CPRX carries more volatility with a beta of 0.74 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 62/100) and 29.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Catalyst Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?